methyl heptine carbonate: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 8092 |
| CHEMBL ID | 3185035 |
| CHEBI ID | 168485 |
| SCHEMBL ID | 158657 |
| MeSH ID | M0079779 |
| Synonym |
|---|
| CHEBI:168485 |
| einecs 203-836-6 |
| nsc 72098 |
| methyl 2-octinate |
| fema no. 2729 |
| methyl oct-2-ynoate |
| ai3-03938 |
| methyl pentylacetylenecarboxylate |
| brn 1756887 |
| vert de violette, artificial |
| nsc72098 |
| 111-12-6 |
| nsc-72098 |
| methyl 2-octynoate |
| 2-octynoic acid, methyl ester |
| methyl hept-1-yne-1-carboxylate |
| methyl heptine carbonate |
| methyl 2-octynate |
| folione |
| methyl 2-octynoate, >=99%, stabilized, fcc, fg |
| methyl 2-octynoate, 99% |
| frlzqxrxikqfns-uhfffaoysa- |
| inchi=1/c9h14o2/c1-3-4-5-6-7-8-9(10)11-2/h3-6h2,1-2h3 |
| O0239 |
| methyl 1-heptyne-1-carboxylate |
| 1-heptyne-1-carboxylic acid methyl ester |
| 2-octynoic acid methyl ester |
| NCGC00248241-01 |
| AKOS009156975 |
| dtxsid9047093 , |
| NCGC00254881-01 |
| dtxcid7027093 |
| tox21_300979 |
| cas-111-12-6 |
| octynoic acid, methyl ester |
| 4-02-00-01715 (beilstein handbook reference) |
| 0ttp6yt2t3 , |
| unii-0ttp6yt2t3 |
| FT-0628470 |
| methylheptine carbonate |
| methyl 2-octynoate [inci] |
| methyl 2-octynoate [fcc] |
| methyl 2-octynoate [fhfi] |
| SCHEMBL158657 |
| methyl heptyne carbonate |
| CHEMBL3185035 |
| J-002525 |
| LMFA07010945 |
| methyl 2-octynoate, analytical standard |
| mfcd00009530 |
| 2-octynoic acid-methyl ester |
| fema 2729 |
| D70492 |
| Q27237243 |
| 2-octynoic acid-methyl ester 1000 microg/ml in acetonitrile |
| AS-56964 |
| methyloct-2-ynoate |
| 2-octynoicacidmethylester |
| CS-W014292 |
| EN300-787196 |
| SY049053 |
| Class | Description |
|---|---|
| fatty acid ester | A carboxylic ester in which the carboxylic acid component can be any fatty acid. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 0.0433 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 0.0017 | 0.0015 | 30.6073 | 15,848.9004 | AID1224849 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 2.4541 | 0.0002 | 29.3054 | 16,493.5996 | AID743075 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 76.9588 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (57.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (35.42) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (28.57%) | 6.00% |
| Case Studies | 1 (14.29%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (57.14%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||